Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Metastatic Colorectal Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVE: Evaluation of complete response rate on treatment combining FOLFIRINOX and panitumumab SECONDARY OBJECTIVE(S): Overall Survival Progression free survival Secondary resection Early tumor shrinkage (ETS) Depth of response (DpR) Safety profile (NCI-CTCAE v4.03 classification) Diagnos...
PRIMARY OBJECTIVE: Evaluation of complete response rate on treatment combining FOLFIRINOX and panitumumab SECONDARY OBJECTIVE(S): Overall Survival Progression free survival Secondary resection Early tumor shrinkage (ETS) Depth of response (DpR) Safety profile (NCI-CTCAE v4.03 classification) Diagnostic performance of ccfDNA analysis compared to the tumor-tissue analysis (current gold standard)
Tracking Information
- NCT #
- NCT02980510
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Thibault MAZARD ICM VAL D'AURELLE
Get Well Soon